New drugs and formulations for pancreatic cancer at ESMO WorldGI: NAPOLI-1 and MPACT trials
- Date: 05 Aug 2014
Speaker: Eric Van Cutsem
Top line results of NAPOLI-1 study:
- What is nal-IRI? What are the mechanisms of action?
- What are the important side-effects?
Searching biomarkers for the treatment of pancreatic cancer with nab-paclitaxel: The SPARC analysis in the phase III MPACT trial